Baker BROS. Advisors LP Decreases Stock Holdings in argenex SE $ARGX

Baker BROS. Advisors LP trimmed its position in argenex SE (NASDAQ:ARGX) by 33.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 25,174 shares of the company’s stock after selling 12,586 shares during the quarter. Baker BROS. Advisors LP’s holdings in argenex were worth $21,170,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. Oppenheimer & Co. Inc. increased its stake in shares of argenex by 2.8% in the fourth quarter. Oppenheimer & Co. Inc. now owns 442 shares of the company’s stock worth $372,000 after buying an additional 12 shares during the period. Valeo Financial Advisors LLC increased its stake in shares of argenex by 0.9% in the fourth quarter. Valeo Financial Advisors LLC now owns 1,372 shares of the company’s stock worth $1,153,000 after buying an additional 12 shares during the period. CI Investments Inc. increased its stake in shares of argenex by 2.6% in the fourth quarter. CI Investments Inc. now owns 469 shares of the company’s stock worth $394,000 after buying an additional 12 shares during the period. Sound View Wealth Advisors Group LLC increased its stake in shares of argenex by 3.4% in the third quarter. Sound View Wealth Advisors Group LLC now owns 396 shares of the company’s stock worth $292,000 after buying an additional 13 shares during the period. Finally, Allworth Financial LP increased its stake in shares of argenex by 12.7% in the fourth quarter. Allworth Financial LP now owns 115 shares of the company’s stock worth $97,000 after buying an additional 13 shares during the period. 60.32% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Wells Fargo & Company lifted their target price on shares of argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a research note on Monday, June 1st. Glj Research upgraded shares of argenex to a “strong-buy” rating in a report on Friday, April 3rd. Royal Bank Of Canada cut their price target on shares of argenex from $925.00 to $890.00 and set an “outperform” rating on the stock in a report on Friday, February 27th. Wall Street Zen cut shares of argenex from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Finally, Robert W. Baird lifted their price target on shares of argenex from $858.00 to $867.00 and gave the company a “neutral” rating in a report on Friday, February 27th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $1,019.50.

argenex Trading Up 1.6%

Shares of ARGX stock opened at $892.26 on Thursday. argenex SE has a 12 month low of $510.05 and a 12 month high of $934.62. The stock has a market cap of $55.49 billion, a PE ratio of 39.73, a price-to-earnings-growth ratio of 1.34 and a beta of 0.47. The company’s fifty day moving average price is $820.36 and its 200-day moving average price is $810.81.

argenex (NASDAQ:ARGX) last announced its earnings results on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. argenex had a net margin of 31.31% and a return on equity of 44.37%. The firm had revenue of $1.31 billion for the quarter. On average, sell-side analysts forecast that argenex SE will post 26.19 earnings per share for the current fiscal year.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.